Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome A multicenter open-label trial in Korea

  • Ahn, Yo Han; 
  • Kim, Seong Heon; 
  • Han, Kyoung Hee; 
  • Choi, Hyun Jin; 
  • Cho, Heeyeon; 
  • 외 10명
Citations

WEB OF SCIENCE

50
Citations

SCOPUS

63

초록

Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids and calcineurin inhibitors (CNIs). Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation consisted of a randomized controlled trial for steroid-and CNI-dependent NS (DDNS; randomization into the RTX group and the control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and DRNS patients received a single dose of intravenous RTX (375mg/m(2) of body surface area) for B-cell depletion. A second RTX dose was administered at week 2 if the first dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS. Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control group (P=.003). The mean duration of remission maintenance was significantly higher in the RTX group than in the control group (9.0 vs 2.9 months, P=.004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1%) achieved partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8% of 59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were mild. Conclusions: RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

키워드

nephrotic syndrome; rituximab; children; LOW-DOSE RITUXIMAB; STEROID-RESISTANT; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; CHILDREN; CYCLOSPORINE; THERAPY; REMISSION; RISK
제목
Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome A multicenter open-label trial in Korea
저자
Ahn, Yo Han; Kim, Seong Heon; Han, Kyoung Hee; Choi, Hyun Jin; Cho, Heeyeon; Lee, Jung Won; Shin, Jae Il; Cho, Min Hyun; Lee, Joo Hoon; Park, Young Seo; Ha, Il-Soo; Cheong, Hae Il; Kim, Su Young; Lee, Seung Joo; Kang, Hee Gyung
DOI
10.1097/MD.0000000000013157
발행일
2018-11
유형
Article
저널명
Medicine
권
97
호
46